Nanomedicine Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and Comprehensive Valuation…

A new intelligence report Nanomedicine Market Was recently added to Nanomedicine Market Research collection of top-line market study reports. International Nanomedicine Market report is a meticulous all-inclusive analysis of this market that provides access to direct firsthand insights on the growth trail of market at near term and long term. On the grounds of factual advice sourced from authentic industry pros and extensive primary business study, the report offers insights about the historical growth pattern of Nanomedicine Market and present market situation. It then provides brief and long-term market growth projections.

Projections are only based on the comprehensive analysis of key Market dynamics that are expected to influence Nanomedicine Market performance and also their seriousness of impacting market growth within the span of assessment interval.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2734725&source=atm

In addition to evaluation of dynamics, the report supplies In-depth examination of key business trends that are anticipated to behave more prominently in global Nanomedicine Market. The study also provides valued information concerning the present and upcoming growth opportunities in Nanomedicine Market the important players and new market entrants can capitalize on.

Competitive Businesses And manufacturers in global market

segment by Type, the product can be split intoQuantum dotsNanoparticlesNanoshellsNanotubesNanodevicesMarket segment by Application, split intooncologyInfectious diseasesCardiologyOrthopedicsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2734725&source=atm

Opportunity assessment offered in this Nanomedicine Market report Is important in terms of understanding the lucrative regions of investment, which prove to be the actionable insights for major market players, providers, distributors, and other stakeholders in Nanomedicine Market.

In-depth global Nanomedicine Market taxonomy presented in this Report offers detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional evaluation of global Nanomedicine Market divides global market landscape into essential geographies.

Regional prognosis and country-wise analysis of Nanomedicine Market Allows for the analysis of multi-faceted operation of marketplace in all of the crucial markets. This information intends to provide a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Taxonomy and geographic analysis of the international Nanomedicine Market enables readers to see profits in present chances and catch upcoming growth chances even until they approach the market location. The analysis given in report is only meant to unroll the economic, societal, regulatory and political situations of this market specific to each area and country, which could help potential market entrants in Nanomedicine Market landscape to comprehend the nitty-gritty of target market areas and invent their plans accordingly.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2734725&licType=S&source=atm

Nanomedicine Market Table of Contents

Read the original:

Nanomedicine Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and Comprehensive Valuation...

Nanomedicine Market Competitive Research And Precise Outlook 2020 To 2026 – Cole of Duty

The global Nanomedicine market report is a comprehensive research that focuses on the overall consumption structure, Demand, Revenue and Forecast till 2026. The report focuses on key companies in the global Nanomedicine industry, market segments, competition, and the growth drivers, constraints and SWOT analysis. This report focuses on Nanomedicine volume and value at the global level, regional level and company level.

(Get up to 20% discount on this)

Request for sample:

https://www.marketinsightsreports.com/reports/07212156415/global-nanomedicine-market-size-status-and-forecast-2020-2026/inquiry?Mode=52

Nanomedicine Market will research at CAGR of 13.5% during the Forecast Period 2017 to 2025.

The Report includestop leading companies Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

Global Nanomedicine Market, By Type

Quantum dots

Nanoparticles

Nanoshells

Nanotubes

Nanodevices

Global Nanomedicine Market, By Application

oncology

Infectious diseases

Cardiology

Orthopedics

Others

Key Market Trends

Neurological Diseases is Expected to Show Better Growth in the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. The Parkinsons Foundation Prevalence Project estimates that 930,000 people in the United States will be living with Parkinson Disease (PD) by the year 2020. This number is predicted to rise to 1.2 million by 2030. Therefore recent years has observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others,

North America is Expected to Hold the Largest Share of the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy.

For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs was developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Furthermore, most of the companies are investing in R&D. Nanotechnology is thus likely to play a significant role in the delivery of drugs, which is expected to further advance the research and development activities, over the forecast period.

Global Nanomedicine Market Segmentation by Region:

North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America

Table of Contents:

Report Overview:It includes Nanomedicine market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Nanomedicine market trends and shares market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Nanomedicine market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Nanomedicine market report is studied on the basis of the market size by application, the market size by product, key players, and market forecast.

Key Players:This part of the Nanomedicine market report discusses expansion plans of companies, key mergers and acquisitions, funding and investment analysis, company establishment dates, revenues of manufacturers, and their areas served and manufacturing bases.

Browse This Report:

https://www.marketinsightsreports.com/reports/07212156415/global-nanomedicine-market-size-status-and-forecast-2020-2026?Mode=52

Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

Marketinsightsreports are inspired to help our clients grow by providing business insight with our huge market intelligence repository.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234

Mob: +91-750-707-8687

[emailprotected]

[emailprotected]

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team

The rest is here:

Nanomedicine Market Competitive Research And Precise Outlook 2020 To 2026 - Cole of Duty

Global Nanotechnology in Medical Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by…

Nanotechnology in Medical Market report involves all together a different chapter on COVID 19 Impact. The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.Download The report Copy form the webstie: https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report

The major players profiled in this report include: Amgen, Merck, Novartis, Roche, Pfizer, Smith and Nephew

Market segment by type can be split into: Nano Medicine, Nano Diagnosis, Other

Market segment by the application can be split into: Hospitals, Clinics, Others

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report#download_report

As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Nanotechnology in Medical globally. This report on Nanotechnology in Medical provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of COVID-19 situation.

Nanotechnology in Medical Market report provide an in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner Nanotechnology in Medical Market revenue by understanding the strategic growth approaches.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Nanotechnology in Medical Market Report 2020 (Coronavirus Impact Analysis on Nanotechnology in Medical Market)

Report provides industry analysis, important insights, and a competitive and useful advantage to the pursuers. The report analyzes different segments and offers the current and future prospects of each segment. Furthermore, this research report contains an in depth analysis of the top players with data such as product specification, company profiles and product picture, sales area, and base of manufacturing in the global Nanotechnology in Medical market. The impact on the supply and demand of the raw materials, due to the COVID-19 is also analyzed in the global Nanotechnology in Medical market.

Additionally, report consists of product life cycle, which discus about the current stage of product. Further, it adds manufacturing cost analysis as well as complete manufacturing process involved. Report also adds supply chain analysis to ensure complete data of market.

Objectives of Nanotechnology in Medical Market Report:To justifiably share in-depth info regarding the decisive elements impacting the increase of industry (growth capacity, chances, drivers and industry specific challenge and risks)To know the Nanotechnology in Medical Market by pinpointing its many sub segmentsTo profile the important players and analyze their growth plansTo endeavor the amount and value of the Nanotechnology in Medical Market sub-markets, depending on key regions (various vital states)To analyze the Global Nanotechnology in Medical Market concerning growth trends, prospects and also their participation in the entire sectorTo inspect and study the Global Nanotechnology in Medical Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2027Primary worldwide Nanotechnology in Medical Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming yearsTo examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market

Access Exclusive Free Sample Report (COVID-19 Impact Analysis Updated Edition): Click Here>Download Sample Report of Nanotechnology in Medical Market Report 2020 (Pandemic Impact Analysis Updated Edition May 2020)

Follow is the chapters covered in Nanotechnology in Medical Market:Chapter 1 Nanotechnology in Medical Market OverviewChapter 2 COVID 19 ImpactChapter 3 Nanotechnology in Medical Segment by Types (Product Uncategorized)Chapter 4 Global Nanotechnology in Medical Segment by ApplicationChapter 5 Global Nanotechnology in Medical Market by Regions (2015-2027)Chapter 6 Global Nanotechnology in Medical Market Competition by ManufacturersChapter 7 Company (Top Players) Profiles and Key DataChapter 8 Global Nanotechnology in Medical Revenue by Regions (2015-2020)Chapter 9 Global Nanotechnology in Medical Revenue by TypesChapter 10 Global Nanotechnology in Medical Market Analysis by ApplicationChapter 11 North America Nanotechnology in Medical Market Development Status and OutlookChapter 12 Europe Nanotechnology in Medical Market Development Status and OutlookChapter 13 Asia Pacific Nanotechnology in Medical Market Development Status and OutlookChapter 14 South America Nanotechnology in Medical Market Development Status and OutlookChapter 15 Middle East & Africa Nanotechnology in Medical Market Development Status and OutlookChapter 16 Nanotechnology in Medical Manufacturing Cost AnalysisChapter 17 Marketing Strategy Analysis, Distributors/ TradersChapter 18 Global Nanotechnology in Medical Market Forecast (2020-2027)Chapter 19 Research Findings and ConclusionGet detailed TOC for Nanotechnology in Medical Market Report @ https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report#table_of_contents.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on to share your research requirements.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report

Read the original here:

Global Nanotechnology in Medical Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by...

Small AI biotech BioXcel surges on positive PhIII results, setting up dementia and Alzheimer’s test – Endpoints News

A small biotech added a few hundred million dollars in market value Monday morning after announcing positive Phase III results from their lead neurology drug.

The drug, known as BXCL501, comes from BioXcel, one of a slate of biotechs that has raised millions in recent years on the promise of using artificial intelligence and other advanced computational techniques to speed up the sluggish pace of drug development. Similar to the more prominent Recursion, the company aimed to use its tech to find compounds that other companies or researchers had validated to some degree and repurpose them, particularly in the areas of neurodegeneration, mental health and immuno-oncology.

Now, in a pair of nearly 400-person Phase III trials for bipolar disorder and schizophrenia, the lead drug effectively calmed patients agitation, as measured by a standard scoring system. It also hit secondary endpoints, showing the effect began as early as 20 minutes after dosing.

The company said it plans to submit for approval in the first quarter of 2021. Their stock soared 31%, from $52.99 to $69.40 pre-market on the news.

In our view, these data are very compelling, Guggenheim Partners Yatin Suneja wrote in a note to investors, and we expect approval in both indications.

Suneja said the results looked in-line or better than Adasuve, the Alexza drug used as the standard of care for agitation. She predicted $500 million in peak sales.

When BioXcel filed for its IPO in 2017, though, the company spent as much time talking about its lead drugs potential in Alzheimers and dementia as it did about schizophrenia. Although further behind, that indication so sought out by biotech in recent years remains the companys largest market potential. A Phase I/II trial is now underway.

The larger focus for investors is dementia, larger market than schizophrenia/bipolar, SunTrusts Robyn Karnauskas wrote in a note to investors.

She said the Phase III numbers supported $800 million in peak sales, while pointing to even greater potential in neurodegeneration. We believe data helps validate targeting a central mechanism related to acute agitation and as such, should help expand BXCL501 into additional indications, she said.

That mechanism involves a reformulation of Pifzers 21-year-old sedation drug Precedex. BioXcel created a sublingual version of the drug that can be given easily and produce a calming effect without knocking a patient out. Specifically, it activated the alpha-2 receptor, the pathway through which norepinephrine, among other neuro-chemicals, travels.

In the Phase III studies, the drug reduced patients excitement score on the Positive and Negative Syndrome Scale for schizophrenia and bipolar disorder. Across 381 schizophrenia patients, those on the high dose had 10.3 point reduction after 2 hours, compared with 8.5 on the low dose and 4.8 on placebo. Across 378 bipolar patients, the high dose arm and 10.4 point reduction, compared with 9.1 on the low dose and 5 on placebo.

Patients also showed statistically significant improvements on the Agitation and Calmness Evaluation Scale (ACES), and clinical global impression.

Social image: Vimal Mehta, BioXcel CEO

Continue reading here:

Small AI biotech BioXcel surges on positive PhIII results, setting up dementia and Alzheimer's test - Endpoints News

How research groups are tackling the problem of biologic drug delivery – Pharmaceutical Technology

]]> What are the challenges to developing more convenient, oral-based biologics? Credit: Shutterstock.

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Over the past few decades, the rise of biologics has been nothing short of meteoric. Between 2010 and 2017, around a quarter of the new molecular entities approved by the US Food and Drug Administration (FDA) fell into this bracket (63 out of a total of 262). That may not sound like a lot, but since biologics are much more expensive than small molecule drugs, they account for most of the worlds top-selling drugs by revenues. They also represent one of the fastest growing categories in pharma.

Unfortunately, biologics have a major downside when it comes to delivery. Unlike small molecule drugs, which can generally be taken orally, biologics are large, complex entities that degrade rapidly in the gastrointestinal tract. Weighing between 200 and 1,000 times the size of a small molecule drug, they almost always need to be delivered via injection or infusion. This is far less convenient than swallowing a pill, not to mention far more costly.

To take diabetes management as an example, most people with diabetes still rely on multiple daily injections. Inhalable insulin has been tried out (as per Exubera in 2006 and Afrezza in 2014) but both suffered with safety concerns and poor sales volume. Oral insulin the holy grail of diabetes treatment has yet to hit the market.

There are dozens of groups around the world intent on creating oral delivery methods. Some focus on modifying the drugs chemical structure to improve their stability in the body. Others focus on the epithelial barrier in the gut if you can make that more permeable, large molecules will be able to pass through more easily.

To give an example of the first approach, researchers at EFPL in Switzerland are working on a method to deliver peptides orally. In 2018, the team developed double bridged peptides a structure with much more stability than a typical amino acid chain. Unfortunately, despite this added stability, most of them still disintegrated in the digestive tract.

Since then, the researchers have found a way to trawl through a peptide library (billions of random peptide sequences, twisted into the double bridged format) to identify the ones that actually are stable. After they have isolated the surviving candidates, they do further tests to find the ones that bind to the disease target.

Its a bit like searching for a needle in a haystack, and this method makes this easy, said Professor Christian Heinis, the lead researcher.

An example of the latter approach comes from Israeli biotech Chiasma. Its Transient Permeability Enhancer (TPE) aims to protect drug molecules from digestive enzymes, as well as triggering the temporary expansion of tight spaces in that gut barrier.

This gives just enough space for the drug molecule to pass into the bloodstream, but not enough space for viruses and bacteria. Last year, the company completed a phase III trial on oral capsules called Mycapssa, which could be used as a maintenance treatment for acromegaly.

There are also a number of oral delivery approaches involving nanoparticles. As the thinking goes: if you incorporate the drug into tiny transporting particles, those particles will be able to protect it from stomach acid, as well as accurately targeting its delivery.

Researchers at Houston Methodist Research Institute in Texas are trialling one such approach, in which a peptide-based drug is chemically linked to fatty acids, and packaged in a nanoparticle. In mouse studies, the animals absorbed almost a quarter of the drug dosage (a lot, considering the typical oral bioavailability for a biologic stands at around 1%).

We know the human body can absorb fatty acids, so we decided to chemically link biological drug molecules to fatty acids to see how well these drugs are absorbed into the gastrointestinal system. It turns out that our transporter approach was effective, saidDr Haifa Shen, Professor of Nanomedicine at Houston Methodist.

Nanotechnology could have many further applications within drug delivery. In particular, it could be used for delivering drugs across the blood-brain barrier, a network of blood vessels that functions a bit like neurological armour. While this barrier protects the brain from harmful chemicals, it also prevents therapeutic agents from getting through.

Researchers at Cedars-Sinai Medical Center in California are working on a new type of nano-immunotherapy, which could deliver cancer drugs directly into brain tumours. Again, they are at an early stage of research, but mouse studies have shown promising results.

Current clinically proven methods of brain cancer immunotherapy do not ensure that therapeutic drugs cross the blood-brain barrier, said Dr Julia Ljubimova, Professor of Neurosurgery and Biomedical Sciences at Cedars-Sinai. Although our findings were not made in humans, they bring us closer to developing a treatment that might effectively attack brain tumours with systematic drug administration.

Another exciting research avenue is microneedles. The promise is clear a minimally invasive, painless technique that could deliver the drug through the skin.

One example is a smart, adhesive insulin-delivery patch, being developed by bioengineers at UCLA. The patch, which is adhesive and resembles a sticking plaster, is pre-loaded with insulin and releases the medicine once blood sugar levels exceed a certain threshold. The technology has been accepted into the FDAs Emerging Technology Program, and human trials could start within the next few years.

US biotech Rani Therapeutics is combining both approaches microneedles and oral biologics delivery with its so-called robotic pill. This capsule, which could be used to deliver a number of biologics, moves through the stomach intact, before reaching the desired location in the gut. Here, it releases biodegradable microneedles, which inject the biologic.

This delivery system is still at an early stage of development, but in preclinical tests it performed as well as a subcutaneous injection. The company also has one human trial to its name a phase I trial for a drug called octreotide, which is normally injected intravenously.

While these research groups, and many others, are seeing promising results in the lab and early trials, it remains to be seen which new delivery methods will become a clinical reality. Given the challenges associated with existing delivery methods, and the seemingly unstoppable rise of biologics, there is everything to play for.

Go here to see the original:

How research groups are tackling the problem of biologic drug delivery - Pharmaceutical Technology

NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 – BioSpace

SHELTON, CT / ACCESSWIRE / July 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that Anil R. Diwan, PhD, President and Executive Chairman of the Company, will participate in the "B. Riley FBR Virtual Infectious Disease Summit - Therapeutics Day" on Tuesday, July 21, 2020. The Conference is organized by B. Riley FBR, Inc. (https://brileyfbr.com/).

Dr. Diwan is invited to participate in Panel #3 at 2020 at 2:10 p.m. ET, entitled "Taming the Severe Disease Presentations". He will briefly discuss the Company's novel nanomedicines platform and the Company's progress in the lead IND-ready candidate for the treatment of shingles rash, NV-HHV-101, as well as in developing a drug candidate against SARS-CoV-2, the cause of COVID-19 global pandemic.

The Company believes that it is close to selecting a clinical candidate worthy of advancing into human clinical trials for the treatment of SARS-CoV-2 infection, based on (i) cell culture effectiveness studies against multiple circulating coronaviruses that employ different cell surface receptors, (ii) a lethal lung infection animal model effectiveness study using hCoV-NL63 infection (a coronavirus that uses the same receptor, ACE2, as SARS-CoV-2, and produced similar disease in the animal model), and (iii) preliminary safety studies in animal model at maximum feasible dosage levels. The Company has disclosed its findings from these studies in previous press releases.

Prior to filing for human clinical trials, NanoViricides plans on conducting studies, towards clinical candidate selection, to further determine the effectiveness against SARS-CoV-2, perform additional drug development studies as may be necessary, and request a pre-IND Meeting with the US FDA for regulatory guidance.

The Company is also working with its regulatory consultants on completing an IND with the US FDA to advance its lead drug candidate NV-HHV-101 into human clinical trials for topical dermal treatment of Shingles rash as the initial indication. In particular, the Company is working on finalizing the clinical trials plan for the anticipated human clinical trials for shingles rash treatment. The Company is also in the process of finalizing clinical trial sites. This process has been adversely affected by the current global COVID-19 pandemic, and in particular, its effects across the USA.

Importantly, nanoviricides are designed to act by a novel mechanism of action, trapping the virus particle like the "Venus-fly-trap" flower does for insects. Antibodies, in contrast, only label the virus for other components of the immune system to take care of. It is well known that the immune system is not functioning properly at least in severe COVID-19 patients.

Additionally, it is well known that viruses escape antibody-drugs via mutations. The Company's "nanoviricide" drug candidates, in contrast, are designed to be broad-spectrum, and therefore virus escape by mutations is expected to be unlikely.

The market size for the treatment of shingles is estimated at approximately one billion dollars by various estimates. These estimates take into account the Shingrix vaccine as well as existing vaccines. About 500,000 to 1 million cases of shingles occur in the USA alone every year.

The market size for our immediate target drugs in the HerpeCide program is variously estimated at billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials. These additional candidates are based on NV-HHV-101, thereby maximizing return on investments and shareholder value.

The Company develops its class of drugs, that we call nanoviricides, using a platform technology. This approach enables rapid development of new drugs against a number of different viruses. A nanoviricide is a "biomimetic" - it is designed to "look like" the cell surface to the virus. The nanoviricide technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.

In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of simultaneously (a) attacking extracellular virus to break the reinfection cycle, and (b) disrupting intracellular production of the virus, thus enabling complete control of a virus infection.

About NanoViricidesNanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is in the process of completing an IND application to the US FDA for this drug candidate. The Company cannot project an exact date for filing an IND because of its dependence on a number of external collaborators and consultants, and the effects of recent COVID-19 restrictions.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls". ]

Contact:NanoViricides, Inc.info@nanoviricides.com

Public Relations Contact:MJ ClyburnTraDigital IRclyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

View source version on accesswire.com:https://www.accesswire.com/598261/NanoViricides-to-Participate-in-Panel-Discussion-at-the-B-Riley-FBR-Virtual-Infectious-Disease-Summit-Today-July-21-2020

Go here to see the original:

NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 - BioSpace

Investigating the Effect of Nano-Curcumin on the Expression of Biofilm | IDR – Dove Medical Press

Parastoo Sharifian,1 Somayeh Yaslianifard,2 Parviz Fallah,3 Siavash Aynesazi,4 Mahmood Bakhtiyari,5 Mohammad Mohammadzadeh2

1Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran; 2Department of Microbiology, School of Medicine, Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran; 3Department of Laboratory Science, Faculty of Allied Medicine, Alborz University of Medical Sciences, Karaj, Iran; 4Department of Microbiology, Faculty of Science, North Branch, Islamic Azad, Tehran, Iran; 5Department of Community Medicine and Epidemiology, School of Medicine, Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

Correspondence: Mohammad Mohammadzadeh Tel +989126767995Email M.mohammadzadeh84@yahoo.com

Background: Pseudomonas aeruginosa is an opportunistic pathogen that causes serious nosocomial infections, especially in immunodeficient patients and cystic fibrosis, cancer, and burned individuals. The biofilm that plays an important role in the virulence of P. aeruginosa is under the regulation of quorum sensing and two-component regulatory systems of bacteria. Curcumin, an active phenolic extract of turmeric has shown an inhibitory effect on the biofilm formation of some pathogenic bacteria. Thus, the present study aims to evaluate the effect of Nano-Curcumin on the expression of major regulatory genes involved in biofilm formation of P. aeruginosa.Materials and Methods: The biofilm formation of P. aeruginosa ATCC 10145 was assessed in the presence of 15, 20, and 25 g/mL concentrations of Nano-Curcumin using the microplate titer method. The effect of Nano-Curcumin on the expression level of regulatory genes were determined by relative reverse transcriptase-realtime PCR.Results: In the absence of Nano-Curcumin, P. aeruginosa strain ATCC 10145 strongly produced biofilm (3+) and in the presence of 15 and 20 g/mL, biofilm formation was reduced to moderate (2+) and weak biofilm producer (1+), respectively. Nano-Curcumin at a concentration of 25g/mL inhibited biofilm formation in P. aeruginosa. The expression of regulatory genes was not affected by biofilm inhibitory concentrations of Nano-Curcumin.Conclusion: The antibiofilm mechanism of Curcumin is not related to the downregulation of regulatory systems of P. aeruginosa and probably it prevents the formation of a complete biofilm structure.

Keywords: Pseudomonas aeruginosa, biofilm formation, Nano-Curcumin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:

Investigating the Effect of Nano-Curcumin on the Expression of Biofilm | IDR - Dove Medical Press

Coronavirus news: Understanding the relationship between nanotechnology and COVID-19 – Free Press Journal

Coronavirus pandemic has swept the world and encompassed all inhabited continents. Initial infections were discovered in December 2019 in the Hubei Province of China. On January 10, 2020, the previously unknown pathogen was identified through next generation sequencing as an RNA virus 2. Its genome sequence showed that the novel virus was similar to SARS-CoV, the virus that caused severe acute respiratory syndrome (SARS) in 20022003, and it was named SARS-CoV-2. The availability of the entire genome led to the development of PCR kits to diagnose patients suffering with COVID-19.

Now, scientists are using nanotechnology as a method to battle the novel coronavirus. However, one of the questions that has arisen is how it would, given the constant evolution of the virus Use of nanotechnology is already helping detect various bacteria and viruses (even in those patients with low viral load), so a mutating virus could also be detected. Also, nano-filters are being used to make nano-filtered face masks. So their main objective is to obstruct the transmission of viruses that remain active even after hand wash, etc. Here the mutations won't matter as the main objective is to filter out the virus irrespective of its structure, says Girish Korde, Director, Profound Healthcare Services.

Explaining nanotechnology, Dr Shailesh Jhawar, Director Critical Care, Apex Hospitals says, Nanotechnology is the engineering of functional systems at the molecular level. The field combines elements of physics and molecular chemistry with engineering to take advantage of unique properties that occur at nanoscale.

But how will nanotechnology help in the pandemic? Dr Kaushik De, Healthcare Research & Consulting, Alpha MD, admits that it would be a costly affair, given how the WHO and scientists from across the world are still trying to pinpoint the lifecycle of the virus. It probably would be a costly affair. But the aerosols (air droplets) or other mutations are theories and could account for a small % of the infected. As you would be aware, for a person to get infected through aerosols - there are multiple factors that need to take place. So despite multiple theories, we see practically that majority of the infected fall in a pattern, and hence there is some level of standardization in terms of diagnosis and treatment for patients. And this pool is huge! So maybe despite the cost factor, it may still be effective in terms of diagnostics and treatment, Dr De explains

Nano medicine & COVID-19

The nanotechnology community can contribute significantly in the fight against COVID-19. Nanomaterials have been used for the development of point-of-care diagnostics, carriers for therapeutics, and vaccine development.

See the original post here:

Coronavirus news: Understanding the relationship between nanotechnology and COVID-19 - Free Press Journal

THE 1918 PANDEMIC: What Happened When the Flu Overwhelmed Humboldt’s Medical System? – Lost Coast Outpost

Volunteer Nurses at the Red Cross Hospital, AKA Northern California Hospital (National Archives)

###

PREVIOUSLY:

###

Do not call the doctors forinformation. They have just about all they can do without answeringunnecessary questions as to whether you may take your child to thedentist; whether a certain out of town school will be closed; andwhether the ice cream parlors are open.

TheHumboldt Times, 22 October 1918

###

In July of 1918, two months after19-year-old Imogene Lockwood started her nursing training at theUnion Hospital in Eureka, she began a diary, realizing, she wrote,that the record would be invaluable when age and ease have made mypresent view of life no longer possible.

In early October of that year, Imogenewas still learning how to balance classes, training and patient carewhen two Austrian travelers staying in Eureka fell ill with SpanishFlu and quickly infected their rooming house hosts. The next day fivemore cases were identified, and infection spread rapidly in HumboldtCounty from there.

By mid-October, local nurses and evenstudents like Imogene were sick with the virus. The mayor of Eurekaurged citizens to report suspected cases and local papers publishedguidance on how to avoid an An Attack of Dread Influenza Germs.Local physician Charles Falk did the same, warning that the flu wasspread from person to person via very small droplets whichcould be spread by coughing or sneezing, forceful talking and more.Falk urged infected individuals to isolate and recommended that allnurses and attendants wear masks to protect themselves against thedisease.

Despite the warnings, local case countscontinued to rise, and area physicians grew frustrated, convincedarea citizens were failing to take the simple ordinary precautionsnecessary to avoid infection. On October 19, the State Board ofHealth moved to close all amusements including dances andmovies and local governments followed suit. Just the day before,Mrs. Ira Russ started building a list of individuals willing to helpHumboldts patients. The list was a precautionary measure,Russ reassured prospective volunteers, and the workload would belight.

Instead, patients were transferred fromoutlying areas to Eurekas hospital and the patient count quicklytopped 100, taxing nurses and doctors. Officials moved to limittransfers and dedicate the Northern California Hospital exclusivelyfor isolation of influenza cases, which would allow fewer nurses tocare for more patients in one location. The arrangement stalled,however, when hospital owner Dr. Falk demanded $1,000 a month for useof the empty facility because of its perfect condition. Falkdidnt care to have it filled with contagious disease butwould be willing to bend if the county could meet his price.

At this time, the local Red CrossCommittee on influenza assembled a corps of nurses and emergencyhousekeepers for homebound patients and when the office in SanFrancisco issued a call for Home Defense nurses, local officialsdenied them, as all were urgently needed here. Organizers alsoasked every woman available to help support overworked nurses.In response, Miss Helen Kramer ran errands in an auto and MissDorothy Notley provided emergency housekeeping and cooking. Othersserved as able and volunteer coordinator Mrs. Russ vowed to getassistance to every case possible which the doctors find in need.When called upon, at least twenty-five volunteers showed up at theRed Cross office to make flu masks.

On October 20, Dr. N H. Bright, presidentof the State Board of Healths predicted waning of the fluthe same day Humboldt County announced its first flu-relatedfatality, and in the next few days more local nurses and doctors fellill. The city of Eureka ordered those serving the public to wearmasks and officials reached an agreement to lease Falks hospital.Health Officer Dr. Mercer also urged small towns, lumber camps, andother centers of population to follow Scotia and Samoas lead inestablishing smaller, temporary flu hospitals in their communities torelieve the burden in Eureka.

The Red Cross drug store shut its doorsbecause all employees were sick and local doctors received word thatmedicine from San Francisco would not be coming due to high demand. Dr. Mercer begged community members to stop congregating in thedowntown districts.

As case counts grew, nurses like Imogenehad to fight their own fear of the virus. On October 23 after fallingill, Imogene admitted that she was almost a coward, andcontemplated giving up nursing so as to not ever hear of germsagain, but she conquered her fear and went back to work, only torelapse just two days later. To her diary she confessed that she waspretty frightened and feared her mother and her brother mightget sick. At that time, at least seven other nurses were also downwith the flu.

To help address the nursing shortage, theRed Cross, with Mrs. Russ in still charge, worked quickly to get theNorthern California Hospital up and running, outfitted with donatedlinens and furniture. Within days the facility had 23 cases and couldaccommodate more than 50. The kitchen was up and running and a numberof women throughout town were preparing and donating food. The countylibrarian managed the hospital office, the requests for assistancewere met with the heartiest cooperation and the women of Eurekawere finding more ways than those suggested to be ofassistance. When Anne Fenwick arrived from San Francisco to visither parents, she spent a full day driving a car for Red Crosshospital managers, running errands and collecting supplies, and waseven prepared to move patients if necessary.

By October 25, Eurekas officialsthought they glimpsed the end of the epidemic and attributed it tothe wearing of the masks and the splendid cooperation of thepeople in every way, but the number of cases being treated at theRed Cross hospital continued to rise. The hospital stopped admittingvisitors, but volunteers were still needed, and one thankful hospitalcommittee member noted that there seemed no limit to the responseof the citizens to help whenever difficulties arose.

On October 28, when only 20 new caseswere reported for the day, Dr. Wing expressed hope that infectionswere decreasing, believing that anti-flu masks had cut the sway ofthe malady short. To support this belief, Wing pointed to reportsfrom Mare Island, where nurses adopted masks early and with no otherprecautionary measures, not a single nurse fell ill.

Unfortunately, the number of casescontinued to fluctuate. Fortuna established an emergency hospital atthe Firemens Hall at Newberg and the Red Cross also took over alodging house to care for patients in Arcata.

Fatalities continued, and doctors andnurses felt the strain as they fought their fears and cared forpatients. On November 1, Imogene visited her mother but stayed on theporch, feeling like some sort of pestilence. Dr. Mercer,exhausted from overwork was forced to take time off and MissMurial MacFarlan, who took over as Acting Health officer when Dr.Mercer fell ill, suffered what was believed to be a nervous breakdowndue to overwork.

Union Labor Hospital (Humboldt State University Special Collections)

By the first of November, the UnionHospital was down ten nurses and Imogene, whose health improved, wasthankful to volunteers who took over everything but the actualnursing. Local papers recognized the valiant work being doneand many lives saved through the effort of local volunteers, thoughsome, like J. F. Buck Buchanan, who was on call wherever andwhenever needed, also fell ill.

By mid-November, the county was sadlylosing nurses, but some, like Miss Neska Alexander, recovered andwent back to work. Retired nurses were asked to come forward as amatter of patriotism, but younger women were discouraged fromvolunteering, in part because they were considered more vulnerable tothe virus.

Physicians and officials implored thepublic to follow health recommendations, wear a mask and sociallydistance. If not, Dr. Mercer believed the disease would continue tospread and the toll of death would rise. Thankfully, manyheeded the warning. On November 11, while Imogene Lockwood and othersrecognized the end of the war, their celebrating was tame andhampered due to grief over losing fellow nurses and theirinability to see the merry smiles behind a mask.

Growing compliance with the maskordinance was credited with a decline in cases in Eureka, but casescontinued in outlying areas. Arcata was forced to repurpose theWomens Club House into a Red Cross Hospital and officials touredthe county to encourage adherence to safety measures. Eventually casecounts started to fall throughout the county and by November 17,temporary isolation hospitals, like the one in Scotia, wereable to close. The Red Cross hospital in Eureka shuttered its doorswhen the last patient was discharged on November 20. After fumigatingthe building with formaldehyde, which not even the most hardy andtenacious bug known to science could survive, it was turned backover the Dr. Falk.

Over the next few months, the fluresurfaced throughout the county, but it never again reached theextremes faced in October and November of 1918 when countlessresidents fell ill, and many died. Undoubtedly many more were savedthanks to the tireless efforts of health care workers and volunteers.

On Jan 1, 1919, with the trauma of theepidemic behind her, nursing student Imogene Lockwood wished herdiary a Happy new year! She also resolved to study, put herprofession first, guard her tongue and strive to be more cultured andrefined. She and the other students faced extra work because of thetime they lost caring for flu patients, but by 1922, Miss ImogeneLockwood and many of her classmates were registered nurses, caringfor patients right where they had trained at the Union Hospitalin Eureka.

###

NEXT WEEK:The impact of the SpanishInfluenza Epidemic on education, religious services, jails, and thebusiness community.

Read more from the original source:

THE 1918 PANDEMIC: What Happened When the Flu Overwhelmed Humboldt's Medical System? - Lost Coast Outpost

Healthcare Nanotechnology (Nanomedicine) Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And…

New Jersey, United States,- Latest update on Healthcare Nanotechnology (Nanomedicine) Market Analysis report published with extensive market research, Healthcare Nanotechnology (Nanomedicine) Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Healthcare Nanotechnology (Nanomedicine) industry. With the classified Healthcare Nanotechnology (Nanomedicine) market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Healthcare Nanotechnology (Nanomedicine) market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Healthcare Nanotechnology (Nanomedicine) market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Healthcare Nanotechnology (Nanomedicine) Market growth opportunities in the industry.

Healthcare Nanotechnology (Nanomedicine) Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Healthcare Nanotechnology (Nanomedicine) market size, volume and value, as well as price data.

Healthcare Nanotechnology (Nanomedicine) Market competition by top Manufacturers:

Healthcare Nanotechnology (Nanomedicine) Market Classification by Types:

Healthcare Nanotechnology (Nanomedicine) Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Healthcare Nanotechnology (Nanomedicine) Market Report:

Cataloging the competitive terrain of the Healthcare Nanotechnology (Nanomedicine) market:

Unveiling the geographical penetration of the Healthcare Nanotechnology (Nanomedicine) market:

The report of the Healthcare Nanotechnology (Nanomedicine) market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Healthcare Nanotechnology (Nanomedicine) Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Healthcare Nanotechnology (Nanomedicine) Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read more:

Healthcare Nanotechnology (Nanomedicine) Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And...

Nanomedicine Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 – 3rd Watch…

New Jersey, United States,- Latest update on Nanomedicine Market Analysis report published with extensive market research, Nanomedicine Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Nanomedicine industry. With the classified Nanomedicine market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Nanomedicine market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Nanomedicine market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Nanomedicine Market growth opportunities in the industry.

Nanomedicine Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Nanomedicine market size, volume and value, as well as price data.

Nanomedicine Market competition by top Manufacturers:

Nanomedicine Market Classification by Types:

Nanomedicine Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Nanomedicine Market Report:

Cataloging the competitive terrain of the Nanomedicine market:

Unveiling the geographical penetration of the Nanomedicine market:

The report of the Nanomedicine market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Nanomedicine Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Nanomedicine Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original here:

Nanomedicine Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 - 3rd Watch...

Nanomedicine Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type and Forecast to 2028 Bulletin Line – Bulletin Line

Most recent report on the global Nanomedicine market

A recent market study reveals that the global Nanomedicine market is likely to grow at a CAGR of ~XX% over the forecast period (2019-2029) largely driven by factors including, factor 1, factor 2, factor 3, and factor 4. The value of the global Nanomedicine market is estimated to reach ~US$ XX Bn/Mn by the end of 2029 owing to consistent focus on research and development activities in the Nanomedicine field.

Valuable Data included in the report:

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market players.

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

See the rest here:

Nanomedicine Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type and Forecast to 2028 Bulletin Line - Bulletin Line

Nanomedicine Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2025 Bulletin Line…

The Nanomedicine Market research report is one of the most comprehensive report about business strategies adopted by different players in this Market. This research study gives the potential headway openings that prevails in the global market. It offers detailed research and analysis of key aspects of the Nanomedicine Market.

The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Nanomedicine Market. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to understand the market.

Impact of COVID- 19 on Nanomedicine Market

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Nanomedicine Market, which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal Nanomedicine Market Players to battle Covid-19 Impact.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=99stra37134

The authentic processes followed to exhibit various aspects of the market makes the data reliable in context to particular time period and industry. This report is highly informative document with inclusion of comprehensive market data associated with the significant elements and subdivision of the Nanomedicine Market that may impact the growth scenarios of the industry. The report may commendably help trades and decision makers to address the challenges and to gain benefits from highly competitive Nanomedicine Market.

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the Nanomedicine Market industry report; it identifies direct or indirect competitors in the market.

Key CompaniesGE HealthcareJohnson & JohnsonMallinckrodt plcMerck & Co. Inc.Nanosphere Inc.Pfizer Inc.Sigma-Tau Pharmaceuticals Inc.Smith & Nephew PLCStryker CorpTeva Pharmaceutical Industries Ltd.UCB (Union chimique belge) S.A

Key parameters which define the competitive landscape of the Nanomedicine Market:

Revenue and Market Share by Player

Production and Share by Player

Average Price by Player

Base Distribution, Sales Area and Product Type by Player

Concentration Rate

Manufacturing Base

Mergers & Acquisitions, Expansion

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Nanomedicine Market.

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast of the following regions:

United States

Central and South America (Brazil, Mexico, Colombia)

Europe (Germany, UK, France, Italy, Spain, Russia, Poland)

China

Japan

India

Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)

The Research Report Provides:

An overview of the Nanomedicine Market

Comprehensive analysis of the market

The segment that accounted for a large market share in the past

The segment that is anticipated to account for a dominant market share by forecasted period

Emerging market segments and regional markets

Segmentations up to the second and/or third level

Analyses of recent developments in the market

Events in the market scenario in past few years

Historical, current, and estimated market size in terms of value and volume

Competitive analysis, with company overview, products, revenue, and strategies

Strategic recommendations to help companies increase their market presence

Lucrative opportunities in the market

Key Points Covered in the Table of Content:

Overview: Along with a broad overview of the Nanomedicine Market, this section gives you the details overview, an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain competitive advantage over their competitors in the Nanomedicine Market.

Study on Key Market Trends: This section of the report offers deeper analysis of latest and future trends of the market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. This research report also provides consumption, production, sales, and other forecasts for Nanomedicine Market.

Regional Growth Analysis: All major regions and countries have been covered in Nanomedicine Market report. The regional analysis will help you to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segment Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Nanomedicine Market. Market participants can use this analysis to make strategic investments in key growth pockets of the Nanomedicine Market.

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=99stra37134

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

More:

Nanomedicine Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2025 Bulletin Line...

What is nanomedicine? | ETPN

The potential of Nanomedicine: why is small different?

Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

At the nano-scale, the surface-to-volume ratio is such that the surface properties are becoming an intrinsic parameter of the potential actions of a particle or material. Coating of the particles and functionalization of their surfaces (even on multiple levels) are in this way extremely common to increase the biocompatibility of the particle and its circulation time in the blood, as well as to ensure a highly selective binding to the desired target.

Nanomedicine has the potential to enable early detection and prevention and to drastically improve diagnosis, treatment and follow-up of many diseases including cancer but not only. Overall, Nanomedicine has nowadays hundreds of products under clinical trials, covering all major diseases including cardiovascular, neurodegenerative, musculoskeletal and inflammatory. Enabling technologies in all healthcare areas, Nanomedicine is already accounting for approximatively 80 marketed products, ranging from nano-delivery and pharmaceutical to medical imaging, diagnostics and biomaterials.

Go here to see the original:

What is nanomedicine? | ETPN

Nanosensors Market to Remain Balanced During the the COVID-19 Period – Cole of Duty

The global nanosensor market is expected to generate revenue worth $536.6 million in 2019, and is projected to reach $1,321.30 million by 2026, to register a CAGR of 11.0% during the forecast period.

Nanoscience is the study of nanoparticles and devices, it includes the use of nanosensor across various fields such as chemical, bio-medical, mechanics, and material science among others. Nanosensor market includes the manufacturing and application of physical, chemical, and biological systems and devices at scales ranging from individual atoms or molecules to around 100 nanometers.

Nanosensor is a revolutionary and a technology that is significant across various industrial domains, including communication, medicine, transportation, agriculture, energy, materials & manufacturing, consumer products, and households. Furthermore, various organizations globally are investing in nano sensor market and its emerging applications.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/13362

Nanoscale sensors and devices provides economical and continuous monitoring of various components of a device such as the structural integrity and performance of bridges, tunnels, rails, parking structures, and pavements over time.

Moreover, communications devices, and other innovations enabled by nanoelectronics support an enhanced transportation infrastructure that can communicate with vehicle-based systems to help drivers maintain lane position, the system deploys various nanosensor to avoid collisions, adjust travel routes to avoid congestion, and improve drivers interfaces to onboard electronics. All these factors are lucrative to create opportunities for the global market.

The key factors such as surge in adoption of nano sensor in medical diagnosis & imaging and technological advancements in nanotech devices drive the growth of the global nano sensor market. However, issues arising in the deployment of nanodevices in extreme conditions and high cost of the technology act as the major barriers, thereby hampering the nano sensor market growth. Furthermore, increase in support and R&D funding from government organizations and emergence of self-powered nanotech devices are anticipated to offer lucrative opportunities for the nano sensor market forecast.

The nanosensor market analysis is studied under type, application, and region. Based on type, the market is categorized into optical, chemical, physical, biosensor, and others. The applications covered in the study include electronics, energy, chemical manufacturing, aerospace & defense, healthcare, and others. The geographical analysis is given for North America, Europe, Asia-Pacific, and LAMEA along with their prominent countries.

The nanosensor market leaders profiled in the report include Agilent Technologies, Inc., Analog Devices, Inc., Applied Nanotech, Bruker Corporation, Honeywell International Inc., Biosensors International Group, Ltd., Kleindiek Nanotechnik GmbH, Omron Corp., Lockheed Martin Corp. and Texas Instruments. These key players adopt various market strategies such as, new product launch and development, acquisition, partnership and collaboration and business expansion to increase the nano sensor market share during the forecast period.

KEY BENEFITS FOR STAKEHOLDERS This study includes the analytical depiction of the global nanosensor market along with the current trends and future estimations to determine the imminent investment pockets. The report presents information regarding the key drivers, restraints, and opportunities. The current market is quantitatively analyzed from 2019 to 2026 to highlight the financial competency of the industry. Porters five forces analysis illustrates the potency of the buyers and suppliers in the industry.

GLOBAL NANOSENSOR MARKET SEGMENTATION

BY TYPE Optical Nanosensor Chemical Nanosensor Physical Nanosensor Biological Nanosensor Others

BY APPLICATION Electronics Energy Chemical Manufacturing Aerospace & Defense Healthcare Others

BY REGION North Americao U.S.o Canadao Mexico

Europeo UKo Germanyo Franceo Russiao Rest of Europe

Asia-Pacifico Chinao Japano Indiao Australiao Rest of Asia-Pacific

LAMEAo Latin Americao Middle Easto Africa

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/13362

Read the original:

Nanosensors Market to Remain Balanced During the the COVID-19 Period - Cole of Duty

Nanomedicine Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type and Forecast to 2028 – Bulletin Line

Most recent report on the global Nanomedicine market

A recent market study reveals that the global Nanomedicine market is likely to grow at a CAGR of ~XX% over the forecast period (2019-2029) largely driven by factors including, factor 1, factor 2, factor 3, and factor 4. The value of the global Nanomedicine market is estimated to reach ~US$ XX Bn/Mn by the end of 2029 owing to consistent focus on research and development activities in the Nanomedicine field.

Valuable Data included in the report:

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market players.

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Link:

Nanomedicine Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type and Forecast to 2028 - Bulletin Line

Healthcare Nanotechnology Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -…

New Jersey, United States,- Latest update on Healthcare Nanotechnology Market Analysis report published with extensive market research, Healthcare Nanotechnology Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Healthcare Nanotechnology industry. With the classified Healthcare Nanotechnology market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Healthcare Nanotechnology market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Healthcare Nanotechnology market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Healthcare Nanotechnology Market growth opportunities in the industry.

Healthcare Nanotechnology Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Healthcare Nanotechnology market size, volume and value, as well as price data.

Healthcare Nanotechnology Market competition by top Manufacturers:

Healthcare Nanotechnology Market Classification by Types:

Healthcare Nanotechnology Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Healthcare Nanotechnology Market Report:

Cataloging the competitive terrain of the Healthcare Nanotechnology market:

Unveiling the geographical penetration of the Healthcare Nanotechnology market:

The report of the Healthcare Nanotechnology market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Healthcare Nanotechnology Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Healthcare Nanotechnology Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See more here:

Healthcare Nanotechnology Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -...

New Comprehensive Report on Nanomedicine Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like – Jewish Life News

Nanomedicine Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Nanomedicine Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/91246

Key Competitors of the Global Nanomedicine Market are: , GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A,

Historical data available in the report elaborates on the development of the Nanomedicine on national, regional and international levels. Nanomedicine Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Major Applications of Nanomedicine covered are:Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

This study report on global Nanomedicine market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/91246

The fundamental purpose of Nanomedicine Market report is to provide a correct and strategic analysis of the Nanomedicine industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Nanomedicine market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Nanomedicine-Market-91246

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Link:

New Comprehensive Report on Nanomedicine Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like - Jewish Life News

Report: New PET radiotracer proven safe and effective in imaging malignant brain tumors – Tdnews

IMAGE:Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injectedview more

Credit: Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas. The radiotracer proved to be a superior, high-contrast imaging diagnostic in patients, visualizing tumors that express low or moderate levels of v3 integrin with high sensitivity.

Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults, with 17,000 diagnoses annually. It is a highly diffuse and invasive disease that is personally devastating and virtually incurable. Once diagnosed, most patients survive less than 15 months, and fewer than five percent survive five years.

The 64Cu-EBRGD radiotracer presented in this study has several unique qualities. The peptide sequence Arg-Gly-Asp (RGD) specifically targets the cell surface receptor v3 integrin, which is overexpressed in glioblastomas. To slow clearance, Evans Blue (EB) dye, which reversibly binds to circulating albumin, is bound to RGD, significantly enhancing target accumulation and retention. The addition of the 64Cu label to EBRGD provides persistent, high-contrast diagnostic images in glioblastoma patients.

This first-in-human, first-in-class study included three healthy volunteers who underwent whole-body 64Cu-EBRGD PET/CT. Safety dataincluding vital signs, physical examination, electrocardiography, laboratory parameters and adverse eventswere collected after one day and after one week. Regions of interest were drawn, time-activity curves were obtained and dosimetry was calculated. Two patients with recurrent glioblastoma also underwent 64Cu-EBRGD PET/CT. Seven sets of brain PET and PET/CT scans were obtained over two consecutive days. Tumor-to-background ratios were calculated for the target tumor lesion and normal brain tissue. One week after radiotracer administration, the patient underwent surgical treatment, and immunohistochemical staining of tumor samples was performed.

64Cu-EBRGD was well-tolerated in patients with no adverse symptoms immediately or up to one week after administration. The mean effective dose of 64Cu-EBRGD was very similar to the effective dose of an 18F-FDG scan. Injection of 64Cu-EBRGD to the patients with recurrent glioblastoma showed high accumulation at the tumor with continuously increased tumor-to-background contrast over time. Post-operative pathology revealed World Health Organization grade IV glioblastoma, and immunohistochemical staining showed moderate expression of the v3 integrin.

In this study, we have demonstrated a potential radiotheranostic agent that is safe, sensitive and highly selective in humans, which infers a future diagnostic tool and breakthrough targeted radiotherapy for glioblastoma patients, said Jingjing Zhang, MD, PhD, of Peking Union Medical College Hospital, Beijing, China. We believe this innovative use of 64Cu-EBRGD will significantly improve therapeutic efficacy and patient outcomes.

64Cu-labeled EBRGD represents a viable model compound for therapeutic applications since 177Lu, 90Y or 225Ac can be substituted for 64Cu, said Deling Li, MD, of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. We are currently studying the 177Lu homolog to treat glioblastoma and other v3 integrin expressing cancers, including non-small cell lung, melanoma, renal and bone, and hope to build on the current wave of radiotherapies like 177Lu-DOTATATE.

###

Abstract 349. First-in-Human Study of a 64Cu-Labeled Long-acting Integrin v3 Targeting Molecule 64Cu-NOTA-EB-RGD in Healthy Volunteers and GBM Patients, Jingjing Zhang, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, and THERANOSTICS Center for Radiomolecular Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; Deling Li, Department of Neurosurgery Beijing, Tiantan Hospital, Beijing City, China; Gang Nu, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland; Richard Baum, THERANOSTICS Center for Radiomolecular Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; Zhaohui Zhu, Department of Nuclear Medicine, Peking Union Medic, Beijing, China; and Xiaoyuan Chen, NIBIB/NIH, Bethesda, Maryland. SNMMIs 67th Annual Meeting, July 11-14, 2020.

Molecular Targeting Technologies, Inc., received an exclusive worldwide commercialization license from NIH for rights that, in part, cover EBRGD radiotherapeutics using various radionuclides. Glioblastoma treatment is among its potential uses.

All 2020 SNMMI Annual Meeting abstracts can be found online at http://jnm.snmjournals.org/content/61/supplement_1.toc.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMIs members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

The rest is here:

Report: New PET radiotracer proven safe and effective in imaging malignant brain tumors - Tdnews

Value of Healthcare Nanotechnology (Nanomedicine) Market Predicted to Surpass US$ by the of 2075 2015 2021 – Bulletin Line

Global Healthcare Nanotechnology (Nanomedicine) market Research presents a Comprehensive scenario Which can be segmented according to producers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Healthcare Nanotechnology (Nanomedicine) business for identifying the growth opportunities, development tendencies and factors limiting the development of the marketplace. This report features forecast market information based on previous and present Healthcare Nanotechnology (Nanomedicine) industry scenarios and growth facets. Each of the Essential regions coated in Healthcare Nanotechnology (Nanomedicine) report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Healthcare Nanotechnology (Nanomedicine) market share and market prognosis of every region from 2020-2027 are presented within this report. A deep study of Healthcare Nanotechnology (Nanomedicine) marketplace dynamics will help the market aspirants in identifying the business opportunities that will lead to accumulation of earnings. This segment can efficiently determine the Healthcare Nanotechnology (Nanomedicine) hazard and key market driving forces.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

The Healthcare Nanotechnology (Nanomedicine) report is segmented to provide a clear and Precise view of this international Healthcare Nanotechnology (Nanomedicine) market statistics and market quotes. Healthcare Nanotechnology (Nanomedicine) report Information represented in the form of graphs, charts, and statistics will show the Healthcare Nanotechnology (Nanomedicine) growth rate, volume, goal customer analysis. This report presents the significant data to all Healthcare Nanotechnology (Nanomedicine) business aspirants which will facilitate useful business decisions.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

The Healthcare Nanotechnology (Nanomedicine) report cover following data points:

Part 1: This part enlists the global Healthcare Nanotechnology (Nanomedicine) marketplace Overview, covering the simple market debut, market analysis by kind, applications, and areas. Healthcare Nanotechnology (Nanomedicine) industry states and prognosis (2020-2027) is presented in this part. Additionally, Healthcare Nanotechnology (Nanomedicine) market dynamics saying the chances, market risk, and key driving forces are studied.

Part 2: This part covers Healthcare Nanotechnology (Nanomedicine) manufacturers profile based On their small business overview, product type, and application. Additionally, the sales volume, Healthcare Nanotechnology (Nanomedicine) product price, gross margin analysis, and Healthcare Nanotechnology (Nanomedicine) market share of every player is profiled in this report.

Part 3 and Part 4: This part presents the Healthcare Nanotechnology (Nanomedicine) competition Based on earnings, earnings, and market share of each producer. Part 4 covers the Healthcare Nanotechnology (Nanomedicine) market scenario based on regions. Region-wise Healthcare Nanotechnology (Nanomedicine) sales and growth (2015-2019) is studied in this report.

America and Europes Healthcare Nanotechnology (Nanomedicine) industry by countries. Under this Healthcare Nanotechnology (Nanomedicine) revenue, market share of those nations like USA, Canada, and Mexico is provided. Under Europe Healthcare Nanotechnology (Nanomedicine) report contains, the countries such as Germany, UK, France, Russia, Italy, Russia and their sales and growth is coated.

Part 7, Part 8 and Part 9: These 3 sections covers Healthcare Nanotechnology (Nanomedicine) The earnings and expansion in these regions are presented in this Healthcare Nanotechnology (Nanomedicine) industry report.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Part 10 and Part 11: This component depicts the Healthcare Nanotechnology (Nanomedicine) marketplace Share, earnings, sales by product type and application. The Healthcare Nanotechnology (Nanomedicine) sales growth seen during 2012-2020 is covered in this report.

Related to Healthcare Nanotechnology (Nanomedicine) market (2020-2027) for every region. The sales channels including indirect and direct Healthcare Nanotechnology (Nanomedicine) advertising, traders, distributors, and future trends are presented in this report.

Part 14 and Part 15: These components present Healthcare Nanotechnology (Nanomedicine) market key Research findings and judgment, research methodology, and data sources are covered.

Therefore, Global Healthcare Nanotechnology (Nanomedicine) report is a complete blend covering all The very important market aspects.

View original post here:

Value of Healthcare Nanotechnology (Nanomedicine) Market Predicted to Surpass US$ by the of 2075 2015 2021 - Bulletin Line